LBA81 Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma

Florian Lordick ,Jerry Huang ,Sang Cheul Oh ,Javier Gallego Plazas ,H.H.F Soo,Hacı Mehmet Türk ,J.W Park,Peter C Enzinger ,Yue Cao ,Kohei Shitara ,P Bhattacharya,Patrapim Sunpaweravong ,Manish A Shah ,Y-J Bang,Jaffer A Ajani ,Senjie Lin ,Diarmuid M Moran ,David H Ilson ,R-H Xu,Éric Van Cutsem

doi:10.1016/j.annonc.2023.10.082

LBA81 Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma

Florian Lordick , Jerry Huang + Show 18 more

https://doi.org/10.1016/j.annonc.2023.10.082

Copy DOI

Journal: Annals of Oncology	Publication Date: Oct 1, 2023
Citations: 1

#Locally Advanced #Metastatic Gastroesophageal Junction + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

LBA81 Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma

Full Text